A venture firm based in China has a multi-billion dollar fund and is interested in companies raising seed/angel to Series A rounds and provides investments that can range up to $50M depending on the opportunity. Series B round will also be considered occasionally in terms of the potentiality. The firm seeks opportunities globally, though it has a preference for companies based in China.
The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.
The firm does not have a management team requirement and will help support early-stage companies with filling management teams, if necessary.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply